Scarica l'app Stockscreener
16.12
5.01%
-0.85
Dopo l'orario di chiusura:
16.12
Precedente Chiudi:
$16.97
Aprire:
$17.27
Volume 24 ore:
398.32K
Relative Volume:
1.35
Capitalizzazione di mercato:
$517.86M
Reddito:
$4.12M
Utile/perdita netta:
$-56.68M
Rapporto P/E:
-2.9082
EPS:
-5.5429
Flusso di cassa netto:
$-51.44M
1 W Prestazione:
-19.36%
1M Prestazione:
-18.83%
6M Prestazione:
-42.43%
1 anno Prestazione:
-34.82%
Intervallo 1D:
$14.78
$18.13
Intervallo di 1 settimana:
$14.78
$19.57
Portata 52W:
$14.78
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
16.12 | 517.86M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume IncreaseStill a Buy? - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? - Yahoo Finance
DNTH Stock Touches 52-Week Low at $16.32 Amid Market Challenges - Investing.com UK
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week LowShould You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 7%Here's What Happened - MarketBeat
Swiss National Bank Sells 2,900 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% HigherStill a Buy? - MarketBeat
Charles Schwab Investment Management Inc. Acquires 1,092 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Deep Track Capital, LP Acquires Significant Stake in Dianthus Th - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's What Happened - MarketBeat
Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus
Cantor Fitzgerald Issues Positive Estimate for DNTH Earnings - MarketBeat
HC Wainwright Brokers Raise Earnings Estimates for DNTH - MarketBeat
FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - Defense World
HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald - Defense World
Dianthus Therapeutics' (DNTH) Outperform Rating Reiterated at Wedbush - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownWhat's Next? - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.5%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Research Analysts Set Expectations for DNTH Q1 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - MSN
Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate - Yahoo Finance
Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks
Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada
Dianthus Therapeutics shares fall as Q4 results miss expectations By Investing.com - Investing.com South Africa
Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks
Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):